This clinical trial focuses on patients with rheumatic diseases, which are conditions that cause pain and inflammation in the joints and muscles. The study will explore the effects of a vaccine called the recombinant zoster vaccine (RZV), which is designed to protect against shingles, a painful rash caused by the same virus that causes chickenpox. The trial will involve patients who are taking medications known as JAK inhibitors (such as baricitinib, tofacitinib, filgotinib, and upadacitinib) either alone or in combination with methotrexate, as well as those taking methotrexate by itself. These medications are used to manage rheumatic diseases by reducing inflammation and suppressing the immune system.
The purpose of the study is to assess how well the immune system responds to the RZV vaccine in these patients. The study will monitor the levels of specific antibodies and immune cells that are expected to increase after vaccination. Participants will receive two doses of the vaccine, and their immune response will be measured one month after the second dose. The study will also track any symptoms that occur after vaccination and examine changes in immune system markers over time.
Throughout the study, researchers will collect information on how the immune system reacts to the vaccine and how long the response lasts. They will also compare the immune response to the RZV vaccine with responses to COVID-19 vaccines in similar patients. The study is expected to provide valuable insights into the effectiveness of the RZV vaccine in people with rheumatic diseases who are taking immunosuppressive medications.



France